The IQGAP2 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma cells with targeted disruption of the IQGAP2 gene. This heterogeneous pool contains diverse editing outcomes, offering a robust loss-of-function model for pooled functional analyses while minimizing clonal bias. The polyclonal format is well-suited for investigating IQGAP2-dependent signaling and cellular behaviors in a cancer context.
The parental A-549 cell line was established from a 58-year-old Caucasian male lung adenocarcinoma and is a standard model for non-small cell lung cancer research. These adherent epithelial cells retain alveolar type II features, including tight junction formation, and are widely used in cancer biology, toxicology, and drug response studies. Performing IQGAP2 knockout in this well-defined background enables precise dissection of scaffold-mediated pathways in lung adenocarcinoma.
IQGAP2 acts as a scaffolding protein at the nexus of cytoskeletal organization, adhesion, and signal transduction. It binds F-actin, calmodulin, and the small GTPases Cdc42 and Rac1, thus regulating actin dynamics and lamellipodia formation. IQGAP2 also interacts with components of the MAPK pathway, including MEK and ERK1/2, and modulates the PI3K/AKT cascade. Upstream activation by EGFR and TGF-??, along with downstream effects on ??-catenin and E-cadherin, positions IQGAP2 as a critical integrator of growth factor and adhesion signaling.
Disruption of IQGAP2 in A-549 cells eliminates its scaffolding function, impairing MAPK signaling, cytoskeletal remodeling, and growth factor responsiveness. This loss is expected to attenuate migratory and invasive behaviors, making the knockout a relevant model for studying epithelial-mesenchymal transition and metastasis. Furthermore, the knockout allows assessment of scaffold protein influences on drug sensitivity within a KRAS-mutant lung adenocarcinoma background.
Applications include western blotting or RT-qPCR for target validation and phospho-ERK1/2 analysis for pathway interrogation. Cellular phenotypes can be assessed via scratch wound healing and Boyden chamber assays, while F-actin organization is visualized by phalloidin staining. Co-immunoprecipitation enables mapping of protein interaction changes. The polyclonal nature is advantageous for population-based screens and drug target validation studies. For inquiries, contact Ascent Research.
